A Double-Blind, Placebo-Controlled, Multicenter, Parallel Group Study to Assess Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With Schizophrenia.

Trial Profile

A Double-Blind, Placebo-Controlled, Multicenter, Parallel Group Study to Assess Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With Schizophrenia.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Mar 2016

At a glance

  • Drugs Bradanicline (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Sponsors Targacept
  • Most Recent Events

    • 21 Oct 2014 Results presented at the 27th Annual Congress of the European College of Neuropsychopharmacology.
    • 16 Dec 2013 Primary endpoint 'Significant change in score on the Schedule-for-Assessment-of-Negative-Symptoms over 24 weeks with TC-5619 vs placebo' has not been met, according to a Targacept media release.
    • 16 Dec 2013 Top-line results reported in a Targacept media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top